688356 Jenkem Technology
- 45.79
- -1.18-2.51%
Jenkem Technology News
Deep*Company* Jiankai Technology (688356): The inflection point has reached and we are looking forward to the future
Jiankai Technology (688356): Short-term product sales are disrupted by multiple factors and the self-research pipeline is progressing in an orderly manner
Jiankai Technology (688356): Negative effects on performance are gradually emerging, and new drugs are being marketed soon
First coverage report of KKY Technology (688356): “Materials+Innovation” for the scarcity standard of high-quality polyethylene glycol CXO, Jiankai Technology is moving forward steadily
Jiankai Technology (688356): Innovative Drug+Medical and Aesthetic Products Double Prove Innovative Capabilities Open a New Chapter Overseas
Jiankai Technology (688356) 2023 Interim Report Review: Short-term disrupted by multiple factors, self-development+customer pipeline promotion is expected to drive a recovery in performance
Jiankai Technology (688356) 2023 semi-annual report review: Performance falls short of expectations due to a decrease in technical service revenue, and the R&D pipeline is progressing in an orderly manner
Jiankai Technology (688356): Affected by the external environment, performance growth is slowing down, overseas business+innovation platform is about to bloom
Jiankai Technology (688356): Hoping for the release of production capacity and the promotion of R&D cooperation
Jiankai Technology (688356): Self-developed irinotecan was approved for phase III clinical trials and successfully extended downstream of the industry chain
Jiankai Technology (688356): Leading multi-scenario applications of PEG and derivatives open up space for growth
Jiankai Technology (688356): Local epidemic factors disrupted the expansion of PEG applications in all aspects of the single Q3 quarter, opening the ceiling for long-term growth
Jiankai Technology (688356): The impact of the epidemic on short-term performance continues to increase innovative research and development
Jiankai Technology (688356): The profit side is in line with expectations. The epidemic prevention and control has slowed down the pace of production
Jiankai Technology (688356) third quarter Review report of 2022: short-term disturbance of epidemic situation waiting for capacity release
Jiankai Technology (688356): Expected low performance in 3Q22, expected to release multiple products
Key Technology (688356): Panjin factory is expected to help order digestion heavyweight self-research product authorization is in sight.
Key Technology (688356): medical PEG leader multi-track layout opens growth space
Jiankai Technology (688356) 2022 report comment: H1 performance is in line with expected income and profit end to maintain steady growth
Key Technology (688356): downstream volume support performance steady growth and continuous increase in R & D and innovation investment
Analysis
Price Target
No Data
No Data